Zuventus Healthcare Ltd. is a part of Emcure Pharmaceuticals Ltd.
Incorporated in 1981, Emcure Group has emerged as a significant force in manufacturing and marketing a broad range of biopharmaceutical products in India and globally. With a presence in over 75 countries, Emcure's goal is to constantly innovate and deliver affordable and high-quality healthcare solutions to people. With a strong focus on research and development, the company offers a wide range of products and services under formulations, biologics, and APIs.
Emcure is ranked as the 13th largest pharmaceutical company (source: AIOCD-AWACS MAT MAR 23) in India.
The Group has emerged as a leader in various therapy segments like Gynaecology, ARV and Blood Related, with a strong presence in Cardiology, Pain and Analgesics, Nephrology, Cephalosporin Injectable, Hepatology, Oncology, Diabetology, Vitamins – Minerals & Nutrients.
The Group has gained a significant advantage due to its diversified and specialized subsidiary companies like Zuventus, Gennova, and Heritage. Headed by a professional team, each of the group companies has utilized its strengths and know-how across therapy segments and geographies to make the Group stronger and well-entrenched.
Emcure's products are available globally in alliance with local and multinational companies to attain leadership. The Group has subsidiaries in Dubai, Brazil, South Africa, Singapore, and Nigeria and branch offices in Russia, Morocco, and Shanghai.
The Group has 13 manufacturing facilities across India, three of which are approved by the USFDA.
Emcure's reputation for excellence in India and internationally results from its deliveries to major global corporations. Emcure Group is also a reliable and proven co-marketing partner, as evident through their collaborative relationship with multinational companies like Sanofi, Roche, B.M.S., etc.
Emcure offers technological expertise across various areas like APIs (first-to-market opportunities in domestic markets), Bio Similars, Novel Drug Delivery Systems, Paragraph IV opportunities in the US, and broad expertise with various dosage forms, Chiral molecules, Peptides, Polymer-based chemistry, and complex products.
Through Zuventus, the Group has emerged as a leader in Acute and Semi Chronic therapies in the Indian Pharmaceutical Market. For further information, click on www.emcure.co.in